New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Medicare drug plans usually cover the pill form of semaglutide for type 2 diabetes. Learn more about coverage and costs.

CHICAGO — Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, regardless of their BMI at drug initiation, researchers ...

Once-weekly semaglutide improved glycemia and reduced weight in adults with type 1 diabetes and obesity without increasing hypoglycemia.

CHICAGO — For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses ...

(HealthDay News) — For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes (T2D ...

Results from the Semaglutide Cardiovascular Outcomes Trial (SOUL) were unveiled as a late-breaking symposia at American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago.